Catalyst Pharmaceuticals (NASDAQ:CPRX) is expecting the FDA to rule on its marketing application for Firdapse, a form of 3,4-diaminopyridine used for the treatment of Lambert …
Galmed Pharmaceuticals (NASDAQ:GLMD) shares are soaring nearly 20% in after-hours trading Wednesday, as the drug maker gets a vote of confidence from Cantor …
Analyst initiates a bullish perspective on Dynavax, ascribing a probability of 95% approval for its lead asset.
Analyst sees higher ad revenue per daily active user growth ahead for Snap and attractive valuation.
Analyst says share weakness does not stem from encouraging news, but points to other underlying concerns.
Supernus investors are running for the hills, but analyst sees elimination of 18 mg dose as a good move.
Though Teva shares took a hit upon the news, the analyst sees an upside to expectations in the distance.
Analyst believes impressive Phase 3 data read-out bolsters expectations for lefamulin’s peak sales potential.
Analyst expected NDA acceptance- but believes the FDA news importantly lowers regulatory risk for ARRY.
Analyst dismisses negative publicity haunting HIIQ as unjustified extrapolation from past settlements.
